Naproxen sodium
important information for the patient.
This medicine should always be used exactly as described in the patient leaflet or as directed by
a doctor, pharmacist, or nurse.
The medicine is intended for use on the skin. The active substance of Naproxen HASCO is
naproxen, which has analgesic and anti-inflammatory effects. Levomenthol causes a cooling sensation
on the skin and has a local anesthetic effect, causing local vasodilation and facilitating the penetration of
naproxen into diseased tissues. Chloral hydrate, due to its mildly irritating properties, causes beneficial,
reflexive vasodilation of blood vessels.
The medicine is used locally for analgesic and anti-inflammatory purposes in muscle and joint pain:
Before starting to use Naproxen HASCO, the patient should discuss it with their doctor, pharmacist, or
nurse.
1/4
Patients with gastrointestinal ulcers and bleeding ulcers should be cautious due to the possibility of
naproxen absorption into the bloodstream.
After applying the gel to the skin, hands should be washed thoroughly.
Contact between the medicine and the eyes or mucous membranes should be avoided. If the gel gets
into the eyes or onto mucous membranes, it should be rinsed off with plenty of water.
The medicine should not be used on damaged skin, open wounds, or skin inflammatory conditions.
During treatment and for 2 weeks after its completion, direct sunlight (including solarium) should be
avoided.
The medicine should be used with caution:
Using Naproxen HASCO in patients with kidney and/or liver function disorders
Particular caution should be exercised when using Naproxen HASCO in patients with liver and/or kidney failure due to the possibility of naproxen absorption into the bloodstream.
The medicine should not be used in children under 3 years of age.
The patient should inform their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
So far, no interactions have been observed between naproxen applied topically to the skin and other medicines. However, in the case of long-term use of the medicine on large areas of skin, it cannot be entirely ruled out that such interactions may occur.
In the case of oral administration of naproxen, it has been observed that:
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
Oral forms (e.g., tablets) of naproxen may cause side effects in the unborn child. It is not known whether the same risk occurs when using Naproxen HASCO on the skin.
Naproxen HASCO should not be used during the last 3 months of pregnancy.
Naproxen HASCO should not be used during the first 6 months of pregnancy, unless it is absolutely necessary and recommended by a doctor. If treatment is necessary during this period, the smallest possible dose should be taken for the shortest possible time.
The medicine should not be used during breastfeeding. Naproxen passes into breast milk.
The medicine does not affect the ability to drive vehicles or operate machinery.
2/4
The medicine may cause skin irritation.
The medicine may cause allergic reactions (possible late-type reactions).
This medicine should always be used exactly as described in the patient leaflet or as directed by
a doctor, pharmacist, or nurse. If in doubt, the patient should consult their doctor, pharmacist, or nurse.
The medicine is for use on the skin.
The medicine should be applied 4 to 5 times a day to the painful area and gently massaged in. On
a skin surface of approximately 7 cm x 7 cm, a 1 cm long strip of gel should be used.
After applying the gel to the skin, hands should be washed thoroughly, unless the treatment includes them.
If redness and skin irritation occur, the use of the medicine should be discontinued until the symptoms resolve. If the symptoms do not resolve, the patient should consult their doctor.
When using naproxen topically, no overdose symptoms are known. However, due to improper use or accidental ingestion, systemic side effects may occur. In such a case, the doctor will apply the appropriate treatment for non-steroidal anti-inflammatory drug poisoning.
In case of accidental ingestion (e.g., by a child), the patient should contact their doctor.
Like all medicines, Naproxen HASCO can cause side effects, although not everybody gets them.
After using the medicine, local skin reactions may occur: hypersensitivity, redness, irritation, usually resolving after discontinuation of the medicine.
In the case of long-term use on large areas of skin, side effects may occur due to the systemic effect of naproxen (e.g., nausea, diarrhea, drowsiness, headaches, hypersensitivity reactions). Photosensitivity reactions are possible. Rarely, erythema, itching, or burning may occur. If shortness of breath or skin changes occur, the use of the medicine should be discontinued immediately, and the patient should consult their doctor or go to the nearest hospital.
Reporting side effects
If any side effects occur, including any possible side effects not listed in the leaflet, the patient should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Aleje Jerozolimskie 181C, 02-222 Warsaw
tel.: 22 49 21 301, fax: 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medicine.
3/4
Store in closed, original packaging, at a temperature below 25°C.
The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiry date stated on the packaging.
The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The gel is homogeneous, white or yellowish, with a minty smell.
One packaging of the medicine contains 50 g of gel.
“PRZEDSIĘBIORSTWO PRODUKCJI FARMACEUTYCZNEJ HASCO-LEK” S.A.
51-131 Wrocław, ul. Żmigrodzka 242 E
Medicine information
tel.: 22 742 00 22
e-mail: informacjaoleku@hasco-lek.pl
Date of last update of the leaflet:08/2024
4/4
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.